Buscar
Arbutus Biopharma Corp
ABUSAñadir a la lista de seguimiento
4.340USD
-0.070-1.59%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
857.31MCap. mercado
5.23P/E TTM
Más Datos de Arbutus Biopharma Corp Compañía
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
Información de Arbutus Biopharma Corp
Símbolo de cotizaciónABUS
Nombre de la empresaArbutus Biopharma Corp
Fecha de salida a bolsaNov 13, 2010
Director ejecutivoAndroski (Lindsay)
Número de empleados44
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 13
Dirección701 Veterans Circle
CiudadWARMINSTER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal18974
Teléfono16044193200
Sitio Webhttps://www.arbutusbio.com/
Símbolo de cotizaciónABUS
Fecha de salida a bolsaNov 13, 2010
Director ejecutivoAndroski (Lindsay)
Ejecutivos de Arbutus Biopharma Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lindsay Androski, J.D.
Ms. Lindsay Androski, J.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Robert Alan Beardsley
Mr. Robert Alan Beardsley
Independent Director
Independent Director
--
--
Mr. Joseph Bishop
Mr. Joseph Bishop
Independent Director
Independent Director
--
--
Mr. Matthew Gline
Mr. Matthew Gline
Independent Director
Independent Director
--
--
Mr. Tuan Nguyen
Mr. Tuan Nguyen
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. Roger Sawhney, M.D.
Dr. Roger Sawhney, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Arbutus Biopharma Corp?
Los cinco principales accionistas de Arbutus Biopharma Corp son: Ms. Lindsay Androski, J.D.
¿Cuántas instituciones poseen acciones de Arbutus Biopharma Corp (ABUS)?
A fecha de 2026Q1, 317 instituciones poseen acciones de Arbutus Biopharma Corp, con un valor de mercado combinado de aproximadamente 128.81M, lo que representa el 65.56% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 6751903.00.